Last reviewed · How we verify
Acupuncture
Acupuncture is a Small molecule drug developed by National Research Centre of Complementary and Alternative Medicine, Norway. It is currently in Phase 2 development. Also known as: sham group.
Acupuncture is a form of alternative medicine that involves inserting thin needles into the body, and it has been studied as a treatment for various conditions, including cancer, pain, and nausea, as well as natural childbirth and postoperative vomiting. Clinical trials have investigated the use of acupuncture, moxibustion, and other interventions, such as TENS, to assess their efficacy in treating these conditions.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Acupuncture |
|---|---|
| Also known as | sham group |
| Sponsor | National Research Centre of Complementary and Alternative Medicine, Norway |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects (NA)
- Stimulation of Acupuncture Points by Athermic Laser Therapy for the Prevention of Chemotherapy Induced Nausea and Vomiting in Children (NA)
- Acupuncture for Blood Pressure Fluctuation During Total Laparoscopic Hysterectomy (NA)
- Acupuncture for Colorectal sUrgery Recovery Enhancement: A Randomized Controlled Trial Evaluating Gastrointestinal Functional Recovery After Minimally Invasive Resection (NA)
- Blood Flow Restricted Resistance Exercises Versus Low Level Laser on Cardiac Functions in Patients With Chronic Heart Failure (NA)
- Fatigue in Sjögren's Syndrome: 3 Therapeutic Strategies (NA)
- Efficacy Evaluation of Electroacupuncture in the Treatment of Functional Dyspepsia (NA)
- The Efficacy and Safety of Shoulder Chuna on in Patients With Shoulder Pain Caused by Traffic Accidents (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acupuncture CI brief — competitive landscape report
- Acupuncture updates RSS · CI watch RSS
- National Research Centre of Complementary and Alternative Medicine, Norway portfolio CI
Frequently asked questions about Acupuncture
What is Acupuncture?
Who makes Acupuncture?
Is Acupuncture also known as anything else?
What development phase is Acupuncture in?
Related
- Manufacturer: National Research Centre of Complementary and Alternative Medicine, Norway — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: sham group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing